-The Indian Express India's role in pharmaceutical patent wars has broadened access to healthcare. Recently, there were rumours that the United States Trade Representative (USTR) was getting ready to announce "trade enforcement actions" or sanctions against India over its intellectual property rights regime. The Obama administration has been under pressure from the US Chamber of Commerce and lobby groups, like the Pharmaceutical Research and Manufacturers of America, to take a tough stance...

-The Telegraph New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection. In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only...

-The Telegraph New Delhi: Many doctors across India have been offered prepaid cash cards as gifts by drug industry representatives over the past three years to try and influence prescriptions for patients, pharmaceuticals sales executives have said. While drug companies have long used largesse as "brand reminders" for doctors, a prepaid cash card leaked by an industry whistleblower appears to be the first evidence to suggest doctors are also being offered cash...

-The Telegraph New Delhi: The price caps imposed by the Indian government on 348 drugs earlier this year have created only an illusion of control, keeping many medicines for conditions ranging from asthma to diabetes and heart disease beyond price regulations, experts said today. The price control order issued by the department of pharmaceuticals in May has led to a 22 per cent reduction in the average cost of some 250 medicines,...

-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...